Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of α-particle-emitting 211At-labeled trastuzumab

This publication has 37 references indexed in Scilit:

• High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer
  Annals of Oncology, 2008
• Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report
  Anti-Cancer Drugs, 2008
• Clinical Experience with α-Particle–Emitting ²¹¹At: Treatment of Recurrent Brain Tumor Patients with ²¹¹At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6
  Journal of Nuclear Medicine, 2007
• Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab
  The Lancet Oncology, 2006
• In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction
  Nuclear Medicine and Biology, 2006
• Treatment of Neuroblastoma Meningeal Carcinomatosis with Intrathecal Application of α-Emitting Atomic Nanogenerators Targeting Disialo-Ganglioside GD2
  Clinical Cancer Research, 2004
• N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with α-particle emitting 211At
  Nuclear Medicine and Biology, 2003
• Long term response in a patient with neoplastic meningitis secondary to melanoma treated with131I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab?)2
  Cancer, 2001
• Chimeric anti-tenascin antibody 81C6: Increased tumor localization compared with its murine parent
  Nuclear Medicine and Biology, 1996
• Carcinomatous meningitis: antibody-guided therapy with I-131 HMFG1.
  Journal of Neurology, Neurosurgery & Psychiatry, 1991